GeneCentric Therapeutics Inc.
04/05/2024 | Press release | Archived content
2024 AACR Annual Meeting – Apr. 5-10, 2024 | San Diego, CA
GeneCentric will present two posters, including data on PurIST for pancreatic ductal adenocarcinoma and our new diagnostic program for colorectal cancer, at the AACR Annual Meeting to be held April 5-10, 2024 in San Diego, CA.
1040 / 20 - Development of a novel RNA-based microsatellite stable predictive response signature (MSS-PRS) to identify MSS colorectal cancer (CRC) patients with a microsatellite instability-high (MSI-H) molecular phenotype
Session PO.CL01.01 - Diagnostic Biomarkers 1
Section 42
Date: April 7, 2024
Time: 1:30pm - 5:00pm
2542 / 2 - Real-world validation of the PurIST classifier demonstrates enhanced therapy selection for pancreatic ductal adenocarcinoma (PDAC) patients
Session PO.CL10.01 - Real-World Biomarkers
Section 45
Date: April 8, 2024
Time: 9:00am - 12:30pm
In addition, please reach out ([email protected]) if you would like to schedule a 1:1 meeting with our team. Learn more about AACR 2024 and register here: https://www.aacr.org/meeting/aacr-annual-meeting-2024/
GeneCentric Therapeutics Inc. published this content on April 05, 2024, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 17, 2026 at 05:28 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]